Drug intelligence / Profile preview

MT-013

Development stage: Preclinical
Lead developer: Marigold Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MT-013 is a bispecific antibody-drug conjugate (Bs-ADC) being developed by Marigold Therapeutics for the treatment of advanced solid tumors. Currently in the discovery phase, MT-013 is designed to target two distinct tumor antigens or epitopes, which may enhance the specificity and internalization of the cytotoxic payload compared to traditional monospecific ADCs. This dual-targeting approach is intended to improve therapeutic efficacy and potentially overcome resistance in various solid tumor types.

Beyond the preview

Go deeper on MT-013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-013.

Explore the full profile